The usefulness and use of second-generation antipsychotic medications: Preface

Current Opinion in Psychiatry

Volumn 15, Issue SUPPL. 1, 2002, Pages

  Sartorius, Norman ^a   Fleischhacker, W W ^a   Gjerris, Annette ^a   Kern, Ursula ^a   Knapp, Martin ^a   Leonard, Brian E ^a   Lieberman, Jeffrey ^a   López Ibor, Juan José ^a   Van Raay, Bas ^a   Twomey, Esther ^a   Kupfer, David J ^a   Angst, J ^a   Cassano, G B ^a   Crow, T J ^a   Freeman, H ^a   Gelder, M G ^a   De Girolamo, G ^a   Katschnig, H ^a   Lader, M H ^a   Leon C A ^a   Mak, F Lieh ^a   Maj, M ^a   Metzler, H Y ^a   Offord, D ^a   Okasha, A ^a   Parker, G ^a   Remschmidt, H ^a   Rutter, M ^a   Simon, G E ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,3,3A,12B TETRAHYDRO 3 METHYL 1H DIBENZO[B,F]OXEPINO[10,11 C]PYRROLE; AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; ILOPERIDONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 2 RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; SERTINDOLE; ZIPRASIDONE; ZOTEPINE;

AGRANULOCYTOSIS; CLINICAL TRIAL; CONFUSION; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; OBESITY; PRACTICE GUIDELINE; PSYCHOPHARMACOLOGY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEIZURE; SEXUAL DYSFUNCTION; TARDIVE DYSKINESIA;

EID: 18344384039     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200203001-00001     Document Type: Review

References (247)

1. Discovery of the clinical use of neuroleptics
2. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia
3. Tardive dyskinesia: Epidemiological and clinical presentation
4. Antipsychotics: Past and future
5. The natural history and pathophysiology of treatment resistant schizophrenia
6. Cost of relapse in schizophrenia
7. Drug therapy: Schizophrenia
8. Predicting the 'revolving door' phenomenon among patients with schizophrenic, schizoaffective, and affective disorders
9. Service provision for people with schizophrenia: I. Clinical and economic perspective
10. Management of mental health and substance abuse services: State of the art and early results
11. New directions in research on involuntary outpatient commitment
12. Managing the care of schizophrenia: Lessons from a 4-year Massachusetts Medicaid study
13. Constitution chimique et action pharmacologique d'un nouveau groupe de neuroleptiques tricycliques
14. Kritische stellungnahme zum begriff der neuroleptika
15. Mechanisms of action of atypical antipsychotic drugs: A critical analysis
16. Duration of a clozapine trial in neuroleptic-resistant schizophrenia
17. Emerging roles for novel antipsychotic medications in the treatment of schizophrenia
18. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: Role of 5HT2 receptors
19. D2 and 5HT2 receptor effects of antipsychotics: Bridging basic and clinical findings using PET
20. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia
21. Psychopharmacological profile of amisulpride: An antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity
22. Improvement of acute exacerbations of schizophrenia with amisulpride: A comparison with haloperidol
23. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: A dose-ranging study vs. haloperidol
24. Amisulpride versus flupenthixol in schizophrenia with predominantly positive symptomatology: A double-blind controlled study comparing a selective D20-like antagonist to a mixed D1-/D2-like antagonist
25. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
26. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia
27. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride
28. Treatment of negative symptoms in schizophrenia with amisulpride
29. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride
30. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
31. Amisulpride: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia
32. Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: Comparison with D2 receptor
33. Pharmacokinetics and metabolism of amisulpride
34. Amisulpride versus haloperidol in treatment of schizophrenic patients: Results of a double-blind study
35. Amisulpride improves affective symptoms in acute schizophrenia
36. Pharmacological profile of amisulpride: An atypical neuroleptic which preferentially blocks presynaptic D2/D3 receptors
37. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia
38. Clozapine: A review of its pharmacological properties and therapeutic use in schizophrenia
39. Extrapyramidal side effects of clozapine and haloperidol
40. Clozapine and haloperidol in a single-blind cross over trial: Therapeutic and biochemical aspects in the treatment of schizophrenia
41. An example of European multicenter trials: Multispectral analysis of clozapine
42. Clozapine: Double-blind control trial in the treatment of acute schizophrenia
43. Clozapine for the treatment-resistant schizophrenic
44. Clozapine: A comparison with other novel antipsychotics
45. The risks and benefits of clozapine vs. chlorpromazine
46. The effect of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
47. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment
48. Maximizing clozapine therapy: Managing side effects
49. Clozapine for treatment-refractory mania
50. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia
51. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects
52. General pharmacology of clozapine
53. Clozapine-induced agranulocytosis: Incidence and risk factors in the United States
54. Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic
55. Clozapine-induced agranulocytosis: A situation report up to August 1976
56. Clozapine pharmacology and tardive dyskinesia
57. Antipsychotic-induced weight gain: A comprehensive research synthesis
58. Weight gain associated with neuroleptic medication: A review
59. Novel antipsychotics: Comparison of weight gain liabilities
60. Diabetic ketoacidosis associated with clozapine treatment
61. Patient response and resource management: Another view of clozapine treatment of schizophrenia
62. Clozapine and haloperidol in moderately refractory schizophrenia: A six-month randomized and double-blind comparison
63. Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome
64. Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial
65. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
66. Cost effectiveness of clozapine in patients with high and low levels of hospital use
67. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study
68. Clozapine dose in the US and Europe: Implications for therapeutic and adverse effects
69. EEG alterations in patients treated with clozapine in relation to plasma levels
70. Sexual disturbances during clozapine and haloperidol treatment
71. Response of patients with treatment-refractory schizophrenia to clozapine within three serum ranges
72. Radioreceptor binding profile of the atypical antipsychotic olanzapine
73. Olanzapine versus placebo, results of a double-blind, fixed-dose olanzapine trial
74. Olanzapine versus placebo and haloperidol
75. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
76. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses
77. Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol
78. Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone, or haloperidol
79. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia
80. Standard olanzapine versus placebo and ineffective dose olanzapine in the maintenance treatment of schizophrenia
81. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
82. Randomised, double blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol
83. Weight gain induced by olanzapine
84. Prolactin levels in olanzapine versus typical and atypical antipsychotics
85. Olanzapine treatment of psychotic and behavioral symptoms in Alzheimer Disease
86. Seroquel: Biochemical profile of a potential atypical antipsychotic
87. ICI-204,636: An initial appraisal of its pharmacological properties and clinical potential in the treatment of schizophrenia
88. Multiple fixed doses of 'seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
89. Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo
90. ICI 20,636: A new atypical antipsychotic drug
91. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia
92. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of, and a demonstrated, partial response to conventional antipsychotic treatment
93. Clinical improvement and tolerability is maintained long term in elderly patients with psychotic disorders treated with quetiapine
94. Patient satisfaction and acceptability of long-term treatment with quetiapine
95. Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders
96. Quetiapine for the treatment of drug-induced psychosis in Parkinson's Disease
97. Biochemical profile of risperidone, a new antipsychotic
98. Pharmacokinetics of clozapine and risperidone: A review of recent literature
99. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: Factors associated with extrapyramidal symptoms
100. Risperidone in the treatment of schizophrenia
101. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol
102. Optimal dose of neuroleptic in acute schizophrenia
103. Risperidone in the treatment of first-episode psychotic patients: A double-blind multi-center study
104. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: Response to low-dose risperidone
105. Optimal risperidone dose in drug-naïve first episode schizophrenia
106. Risperidone in acutely exacerbated schizophrenia: Dosing strategies and plasma levels
107. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics
108. A qualitative assessment of the neurological safety of antipsychotic drugs: An analysis of a risperidone database
109. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia
110. Neuroleptic-induced hyperprolactinemia
111. Prolactin levels and adverse events in patients treated with risperidone
112. The negative component in schizophrenia
113. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome
114. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
115. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia
116. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia
117. Antipsychotic drugs and relapse prevention
118. Risperidone in childhood schizophrenia
119. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat
120. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia
121. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia
122. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia
123. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
124. Ziprasidone
125. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential
126. Ziprasidone 40 and 20 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo controlled trial
127. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder
128. Ziprasidone: Efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia
129. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors
130. Elevation of extracellular cortical noradrenaline may contribute to the antidepressant activity of zotepine: An in vivo microdialysis study in freely moving rats
131. Steady-state serum kinetics of zotepine
132. Zotepine vs. haloperidol in paranoid schizophrenia: A double-blind trial
133. Double-blind comparison of 3 × 75 mg zotepine and 3 × 4 mg haloperidol in acute schizophrenics
134. Zotepine versus perazine in paranoid schizophrenia: A double-blind controlled trial of antipsychotic efficacy
135. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol, in patients with acute exacerbation of schizophrenia: A parallel-group double-blind trial
136. Efficacy and tolerance of zotepine in a double-blind comparison with perazine in schizophrenics
137. A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia
138. Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms: A double blind trial vs. haloperidol
139. Pharmacological treatment of schizophrenia
140. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis
141. Effectiveness of second-generation antipsychotics in treatment-resistant schizophrenia: A review and meta-analysis of randomized trials
142. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta regression analysis
143. Efficacy and extrapyramidal effects of the new antipsychotics Olanzapine, Quetiapine, Risperidone and Sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
144. Aktuelle bewertung neuer/atypischer neuroleptika
145. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia
146. Atypical antipsychotic drugs in treatment-refractory schizophrenia
147. Clozapine and risperidone in chronic schizophrenia: Effects on symptoms, parkinsonian side effects, and neuroendocrine response
148. Clinical and biologic response to clozapine in patients with schizophrenia
149. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis
150. Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial
151. Quality of life in schizophrenia: Long-term follow-up in 362 Spanish schizophrenic outpatients undergoing risperidone treatment
152. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial
153. Risk factors for clozapine discontinuation among 805 patients in the VA hospital system
154. Do phase III trials have clinical value?
155. Case series: Spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia
156. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
157. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial
158. New atypical antipsychotics: Experience and utility in the elderly
159. Drugs of the psychopharmacological revolution in clinical psychiatry
160. Clozapine dosages and plasma drug concentrations
161. Effects of gender and age on plasma levels of clozapine and its metabolites: Analyzed by critical statistics
162. Reduced haloperidol: A factor in determining the therapeutic benefit of haloperidol treatment?
163. Disposition of olanzapine in Chinese schizophrenic patients
164. The concept of supersensitivity psychosis. The particular case of clozapine
165. Clozapine withdrawal: Serotonergic or dopaminergic mechanisms?
166. Rebound insomnia after abrupt clozapine withdrawal
167. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics
168. Sulpride augmentation in people with schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled study
169. Development of novel antipsychotic drugs
170. Acute and long-term efficacy and safety of aripiprazole: A new atypical antipsychotic
171. Clinical experiences of OPC-14597, a dopamine autoreceptor agonist in schizophrenic patients
172. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2 (1H)-quino linone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity
173. Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain
174. Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area
175. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum
176. Safety and efficacy profile of aripiprazole, a novel antipsychotic
177. Iloperidone binding to human and rat dopamine and 5-HT receptors
178. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic
179. Central 5-HT1A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men
180. The behavioural and pharmacological profile of ORG 5222, a novel atypical antipsychotic
181. Chronic ORG 5222 attenuates 5-HT2C but not 5-HT1C or dopamine mediated behaviour
182. Binding profile of ORG 5222 at cloned human dopamine D2, D3 and D4 receptors
183. The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the pay test: Effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine
184. Hyperfunction of dopaminergic and serotonergic neural systems in mice lacking the NMDA receptor epsilon 1 subunit
185. The cost of schizophrenia
186. Health economics and cost implications of anxiety and other mental disorders in the United States
187. An economic evaluation of schizophrenia - 1991
188. Some aspects of the costs of schizophrenia
189. Health care expenditure on schizophrenia patients in Belgium
190. The costs of schizophrenia
191. Economics and schizophrenia: The real cost
192. Cost of schizophrenia
193. Cost of schizophrenia to UK society: An incidence-based cost-of-illness model for the first 5 years following diagnosis
194. The economic costs of schizophrenia
195. Modelling the lifetime costs of treating schizophrenia in Australia
196. Die direkten und indirekten kosten der schizophrenie
197. The cost of schizophrenia
198. The economic burden of schizophrenia in Canada
199. Costs of schizophrenia in the Netherlands
200. Cost of services of schizophrenic patients in Norway
201. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia
202. Financial cost of treating outpatients with schizophrenia in Nigeria
203. Mental health economic studies from the developing countries reviewed in the context of those from developed countries
204. The use of a case register to evaluate the cost of psychiatric care
205. How expensive is the comprehensive health care of schizophrenic patients living in the community? A cost evaluation from a German catchment area
206. Utilisation of mental health services and costs of patients with schizophrenia in three areas of Spain
207. Costs of schizophrenia, a review
208. The hidden cost of schizophrenia
209. Current topics in clinical psychopharmacology. Economic outcomes of antipsychotic agents in a Medicaid population: Traditional agents vs. risperidone
210. Economic outcomes associated with the use of risperidone in a naturalistic group practice setting
211. Use of health care resources by patients treated with risperidone versus other antipsychotic agents
212. Treatment costs and patient outcomes with use of risperidone in a public mental health setting
213. Medico-economic assessment of neuroleptics in schizophrenia: Amilsulpride versus haloperidol
214. A two-year clinical and economic follow-up of patients on clozapine
215. Cost-effectiveness of clozapine in neuroleptic-resistant schizophrenia
216. Cost-effectiveness of clozapine
217. Evaluation medico-economique du traitement par la crozapine versus les traitements neuroleptiques anterieurs
218. Health care costs of therapy-refractory schizophrenic patients treated with clozapine: A study in a community psychiatric service in Italy
219. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: A retrospective analysis using the Saskatchewan Health Linkable Databases
220. Long-term healthcare resource utilisation and costs before and after initiation of risperidone treatment in patients with chronic schizophrenia
221. Risperidone: Clinical outcome predictors and cost-effectiveness in a naturalistic setting
222. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia
223. Economic impact of the use of risperidone for the treatment of chronic schizophrenia in Ireland
224. Risperidone: A pharmacoeconomic review of its use in schizophrenia
225. Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study
226. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: Results from a randomized trial
227. Formulary decisions and health economics
228. Pharmacoeconomic evaluation of treatments for refractory schizophrenia: Clozapine-related studies
229. Olanzapine: A pharmacoeconomic review of its use in schizophrenia
230. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals
231. Mixed model imputation of cost data for early discontinuers from a randomized clinical trial
232. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia
233. Functional outcomes in schizophrenia: A comparison of olanzapine and haloperidol in a European sample
234. The Risperidone Outcome Study of Effectiveness (ROSE): A model for evaluating treatment strategies in typical psychiatric practice
235. Introduction of antipsychotic agents: Clinical, economic and legal considerations in the treatment of psychosis
236. The classification of depressions: A review of contemporary confusions
237. Problems with implementing guidelines: A randomized controlled trial of consensus management of dyspepsia